A leading position
in an attractive market

  • PolyPeptide well positioned with multi-site manufacturing and development network and rich pipeline

Rapid portfolio shift
driven by GLP-1

  • Growth across therapeutical areas, with mix shifting towards metabolic and large pharma customers

for growth

  • Three new large agreements concluded in 2023; together with agreement previously announced in December 2022, they have the potential to double PolyPeptide’s revenue

2023 – transformation underway with record revenue growth of 43% in H2 2023 vs H1 2023.

Peter Wilden

Chair of the Board of Directors

Juan José González

Chief Executive Officer